Develops a pipeline of innovative therapies addressing a range of diseases through its asset-centric R&D model.
Centessa Pharmaceuticals plc operates as an innovative clinical-stage pharmaceutical company dedicated to discovering, developing, and delivering groundbreaking medicines to patients worldwide. At the forefront of its robust pipeline are registrational products like Lixivaptan, a vasopressin V2 receptor inhibitor currently advancing through Phase III clinical trials for the treatment of autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa trials aimed at addressing hemophilia A and B.
Centessa Pharmaceuticals also boasts an emerging pipeline featuring several clinical proof-of-concept products. Among these are LB101 and LB201, novel PD-L1xCD47 and PD-L1xCD3 LockBodies designed to enhance CD47 and CD3 effector functions while minimizing systemic toxicity. ZF874, a pharmacological chaperone folding corrector, targets alpha-1-antitrypsin deficiency and is currently in Phase I clinical development. The company's pipeline further includes MGX292, a recombinant modified BMP9 replacement protein for Pulmonary Arterial Hypertension, and OX2R Agonists, oral and intranasal treatments for Narcolepsy Type 1 that target orexin neuron loss.
Founded in 2020 and headquartered in Altrincham, United Kingdom, Centessa Pharmaceuticals is committed to advancing therapies across various therapeutic areas. Exploratory products like CBS001, an anti-LIGHT antibody, and CBS004, a humanized mAb specific to BDCA2, demonstrate the company's dedication to addressing inflammatory and autoimmune diseases. With a focus on innovation and patient care, Centessa Pharmaceuticals plc strives to redefine treatment standards and improve outcomes for patients globally.